Deep Tech Startups

Sylvatica Bio develops organ and tissue preservation technologies, including supercooling methods that extend the viability of human organs such as livers outside the body. Its work targets transplantation, regenerative medicine, and drug discovery within biomedicine.

2 investors

Symbolic Mind develops a CPU-efficient AI platform designed for corporate infrastructure that reduces computational requirements by over 100x compared to traditional AI models. The platform serves chipmakers, server manufacturers, and data centers seeking to deploy AI without excessive power, cooling, or infrastructure overhaul.

2 investors

Symeres provides pharmaceutical quality management systems, drug discovery and development services, and contract manufacturing support for biotech and pharma companies. The company operates GMP, GLP, and ISO-certified facilities across Europe and North America to support molecules from early discovery through regulatory submission and manufacturing.

2 investors

Sympheny provides software for multi-energy systems optimization, helping engineering firms, utilities, municipalities, and developers plan renewable energy transitions efficiently. The platform emerged from energy research at Empa and ETH Zürich and uses industrial-grade optimization algorithms to evaluate technology and capacity combinations.

2 investors

Symphorna is developing a therapeutic platform for multi-RNA combination medicines that deliver combined mRNAs and siRNAs alongside a predictive design loop to target multiple disease pathways at once. It focuses on complex conditions such as fibrosis, heart failure, and neurodegeneration, with lung fibrosis as its initial proving ground.

2 investors

Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples. The technology targets clinical applications including oncology and early cancer detection, residual disease and treatment monitoring, drug development, and chronic disease detection.

2 investors

Synkrino Biotherapeutics develops SATIS, an AI-based system for drug discovery. The company operates in the biotechnology sector.

2 investors

Synplexity produces large-scale, cost-effective gene libraries for synthetic biology applications using microreactor technology. The company serves researchers in drug discovery, protein engineering, and functional screening across life sciences and biotechnology.

2 investors

Synplogen is a synthetic biology startup spun out of Kobe University that offers custom artificial gene synthesis and DNA library construction services using its proprietary OGAB and Combinatorial-OGAB (Combi-OGAB) DNA assembly methods. It also operates a gene-therapy biofoundry that designs, develops, and analyzes gene-therapy products such as viral vectors, including CMC development work.

2 investors

SynSense develops brain-inspired (neuromorphic) computing chips and sensing technology for artificial intelligence applications. The company works in the AI semiconductor and deep tech space.

2 investors

Synteris develops advanced ceramic materials using its proprietary SLRS process, with applications including DoD/DARPA hypersonic flight programs. The company focuses on non-oxide ceramics and the commercialization of early-stage materials science innovations.

2 investors

SynthLabs develops reinforcement learning methods for large reasoning models, such as Adaptive Length Penalty (ALP), which adjusts generation length to problem difficulty to reduce token usage. Its work targets AI research and the development of more efficient reasoning models.

2 investors

Synthefy develops Nori, an open-weight foundation model for tabular prediction that returns predictions from labeled context without fitting or training a new model. The model is offered as open source under Apache 2.0 and via a managed hosted API, positioned as an alternative to tools like XGBoost.

2 investors

SynVaccine develops technology for the computer-aided design and construction of viral genomes, applying synthetic and computational biology to create viral-based products such as vaccines and viral-based therapeutics. The company targets applications in human pharma and animal health.

2 investors

Tachyon develops particle accelerator technology and infrastructure at the frontier of applied physics. The company is building hardware and systems for advanced physics applications, with a team of scientists and engineers from SpaceX, national laboratories, and related deep tech organizations.

2 investors

Tactile Orthopaedics develops high-fidelity surgical simulation models for orthopedic training, including knee arthroscopy simulators validated for surgical skill development. The company serves orthopedic surgeons and surgical training programs in medical education.

2 investors

TactoTek provides design tools, reference designs, and technical resources for In-Mold Structural Electronics (IMSE) manufacturing, serving designers, engineering firms, and manufacturers across the product development lifecycle. The company offers digital tools, feature libraries, and knowledge bases to support the design and production of IMSE parts from concept to mass production.

2 investors

Talaria Scientific is building a multi-agent software harness for computational science research, automating routine work like data wrangling, system administration, and validation while keeping the scientist in the loop and using HPC as a guardrail. The open-source tool is aimed at researchers and is currently in private beta.

2 investors

Valo builds an AI-driven drug discovery and development platform that combines real-world human data, causal inference, statistical genetics, and predictive chemistry to identify disease targets and engineer small-molecule compounds. It applies closed-loop modeling and laboratory capabilities to advance lead compounds into drug candidates.

2 investors

Tardid is a deep-tech company that builds physics-driven, model-based AI systems for decision intelligence and situational awareness across defense, maritime, transportation, and industrial domains. Founded in 2016, its offerings include AI platforms, autonomous ISR/survey systems, structural integrity assessment tools, and AI-optimized electric marine propulsion.

2 investors

Circio is a biotech company developing circular RNA technology (circVec) to improve AAV gene therapy expression for the treatment of genetic diseases. It focuses on gene and cell therapy research applications.

2 investors

TATUM bioscience develops biotech solutions, though the page provides limited detail on specific products or target markets.

2 investors

Taut is developing a new approach to artificial intelligence aimed at addressing core problems such as robustness, security, interpretability, and heavy demands on training data and computing resources. The team consists of computer scientists, neuroscientists, mathematicians, and engineers from Caltech, Berkeley, and UCLA.

2 investors

Taysha Gene Therapies develops and commercializes gene therapies for monogenic diseases of the central nervous system, serving patients with rare and larger CNS conditions. Its lead clinical program targets Rett syndrome, alongside a broader pipeline of CNS programs.

2 investors